Role of luteinising hormone releasing hormone (LHRH) agonists and hormonal treatment in the management of prostate cancer

European Urology, Supplements

Volumn 4, Issue 5, 2005, Pages 4-13

  Mongiat Artus, P ^a   Teillac, P ^a  

^a Department of Urology ^*  (France)

Author keywords

Adjuvant therapy; Advanced prostate cancer; Biochemical recurrence; Early prostate cancer; LHRH agonists; Metastatic prostate cancer; Neoadjuvant therapy; Prostate cancer; Review

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ADVERSE DRUG REACTION; ANEMIA; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG SAFETY; EARLY CANCER; ENERGY; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LYMPH NODE METASTASIS; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; ORCHIECTOMY; OSTEOPOROSIS; PAIN; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

EID: 20344399162     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2005.04.003     Document Type: Article

References (90)

1. C. Huggins, R.E. Stevens Jr., and C.V. Hodges Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland Arch Surg 43 1941 209 223
2. D.P. Byar, and D.K. Corle Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies NCI Monogr 7 1988 165 170
3. C. Chang, A. Saltzman, S. Yeh, W. Young, E. Keller, and H.J. Lee Androgen receptor: an overview Crit Rev Eukaryot Gene Expr 5 2 1995 97 125
4. M. Koppan, A. Nagy, A.V. Schally, A. Plonowski, G. Halmos, and J.M. Arencibia Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice Prostate 38 2 1999 151 158
5. D. Dondi, P. Limonta, R.M. Moretti, M.M. Marelli, E. Garattini, and M. Motta Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop Cancer Res 54 15 1994 4091 4095
6. F. Labrie Intracrinology Mol Cell Endocrino 78 3 1991 C113 C118
7. K. Kimura, M. Markowski, C. Bowen, and E.P. Gelmann Androgen blocks apoptosis of hormone-dependent prostate cancer cells Cancer Res 61 14 2001 5611 5618
8. G.J. Bubley Is the flare phenomenon clinically significant? Urology 58 2 Suppl 1 2001 5 9
9. C. Mahler Is disease flare a problem? Cancer 72 12 Suppl 1993 3799 3802
10. M. Shahidi, A.R. Norman, J. Gadd, R.A. Huddart, A. Horwich, and D.P. Dearnaley Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer Clin Oncol (R Coll Radiol) 13 4 2001 291 295
11. M.C. Hall, R.J. Fritzsch, A.I. Sagalowsky, A. Ahrens, B. Petty, and C.G. Roehrborn Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer Urology 53 5 1999 898 902
12. U.W. Tunn, U. Bargelloni, S. Cosciani, G. Fiaccavento, S. Guazzieri, and F. Pagano Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer Urol Int 60 Suppl 1 1998 9 16
13. D.A. Loblaw, D.S. Mendelson, J.A. Talcott, K.S. Virgo, M.R. Somerfield, and E. Ben-Josef American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer J Clin Oncol 22 14 2004 2927 2941
14. D.G. Mcleod Hormonal therapy: historical perspective to future directions Urology 61 2 Suppl 1 2003 3 7
15. W.A. See Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer Curr Treat Options Oncol 4 5 2003 351 362
16. J.W. Moul, and J.E. Fowler Jr. Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003 Urology 62 6 Suppl 1 2003 20 28
17. L. Boccon-Gibod, A. Bertaccini, A.V. Bono, B. Dev Sarmah, W. Holtl, and N. Mottet Management of locally advanced prostate cancer: a European consensus Int J Clin Pract 57 3 2003 187 194
18. F. Debruyne Hormonal therapy of prostate cancer Semin Urol Oncol 20 3 Suppl 1 2002 4 9
19. J.A. Eastham, and P.T. Scardino Radical prostatectomy P.C. Walsh A.B. Retik E.D. Vaughan A.J. Wein Campbell's Urology 1998 W.B. Saunders Company Philadelphia 2547 2564
20. H.M. Sandler Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy J Urol 172 2004 S38 S41
21. A. Blana, B. Walter, S. Rogenhofer, and W.F. Wieland High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience Urology 63 2 2004 297 300
22. F. Labrie, L. Cusan, J. Gomez, P. Diamond, R. Suburu, and M. Lemay Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone -releasing hormone agonist Urology 44 1994 29 37
23. F. Abbas, and P.T. Scardino Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary Urol Clin North Am 23 4 1996 587 604
24. P. Teillac Is there a place for neoadjuvant hormonal therapy before radical prostatectomy or radiation therapy in the management of prostate cancer? Prostate Cancer Prostatic Dis 2 S2 1999 S8 S11
25. E.M. Messing, J. Manola, M. Sarosdy, G. Wilding, E.D. Crawford, and D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
26. E. Messing, J. Manola, M. Sarosdy, G. Wilding, D. Crawford, and D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886 J Urol 169 Suppl 2003 396 (abs. 1480)
27. G.E. Hanks, A.L. Hanlon, W.H. Pinover, E.M. Horwitz, R.A. Price, and T. Schultheiss Dose selection for prostate cancer patients based on dose comparison and dose response studies Int J Radiat Oncol Biol Phys 46 4 2000 823 832
28. G.E. Hanks Conformal radiotherapy for prostate cancer Ann Med 32 1 2000 57 63
29. S. Nag, D. Beyer, J. Friedland, P. Grimm, and R. Nath American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer Int J Radiat Oncol Biol Phys 44 4 1999 789 799
30. A.A. Martinez, I. Pataki, G. Edmundson, E. Sebastian, D. Brabbins, and G. Gustafson Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report Int J Radiat Oncol Biol Phys 49 1 2001 61 69
31. H. Zincke, W. Lau, E. Bergstralh, and M.L. Blute Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer J Urol 166 6 2001 2208 2215
32. EAU Guidelines for prostate cancer. March 2005.
33. M.V. Pilepich, J.M. Krall, M. Al-Sarraf, M.J. John, Doggett RLS, and W.T. Sause Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group Urology 45 1995 616 623
34. M.V. Pilepich, K. Winter, M.J. John, J.B. Mesic, W. Sause, and P. Rubin Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
35. M. Bolla, D. Gonzalez, P. Warde, J.B. Dubois, R.-O. Mirimanoff, and G. Storme Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
36. M. Bolla, L. Collette, L. Blank, P. Warde, J.B. Dubois, and R.O. Mirimanoff Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 108
37. M.V. Pilepich, R. Caplan, R.W. Byhardt, C.A. Lawton, M.J. Gallagher, and J.B. Mesic Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1997 1013 1021
38. C.A. Lawton, K. Winter, K. Murray, M. Machtay, J.B. Mesic, and G.E. Hanks Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946
39. G.E. Hanks, T.F. Pajak, A. Porter, D. Grignon, H. Brereton, and V. Venkatesan Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
40. R.A. Zimmerman, and D.J. Culkin Clinical strategies in the management of biochemical recurrence after radical prostatectomy Clin Prostate Cancer 2 2003 160 166
41. M.A. Khan, and A.W. Partin Management of patients with an increasing prostate-specific antigen after radical prostatectomy Curr Urol Rep 5 2004 179 187
42. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
43. F.H. Schröder Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects BJU Int 83 1999 161 170
44. J.W. Moul Prostate specific antigen only progression of prostate cancer J Urol 163 2000 1632 1642
45. M.H. Rashid, and U.B. Chaudhary Intermittent androgen deprivation therapy for prostate cancer Oncologist 9 2004 295 301
46. H. Miyamoto, E.M. Messing, and C. Chang Androgen deprivation therapy for prostate cancer: current status and future prospects Prostate 61 4 2004 332 353
47. R. Kurek, H. Renneberg, G. Lübben, E. Kienle, and U.W. Tunn Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer Eur Urol 35 Suppl 1 1999 27 31
48. N. Bruchovsky, L.H. Klotz, M. Sadar, J.M. Crook, D. Hoffart, and L. Godwin Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations Mol Urol 4 3 2000 191 199
49. D. Prapotnich, K. Fizazi, B. Escudier, A. Mombet, N. Cathala, and G. Vallancien A 10-year clinical experience with intermittent hormonal therapy for prostate cancer Eur Urol 43 3 2003 233 239
50. M.G. Oefelein Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer J Urol 169 1 2003 251 255
51. M.A. Khan, and A.W. Partin Management of high-risk populations with locally advanced prostate cancer Oncologist 8 3 2003 259 269
52. J.W. Moul Contemporary hormonal management of advanced prostate cancer Oncology (Huntingt) 12 4 1998 499 505
53. G. Auclerc, E.C. Antoine, F. Cajfinger, A. Brunet-Pommeyrol, C. Agazia, and D. Khayat Management of advanced prostate cancer Oncologist 5 1 2000 36 44
54. L.J. Denis Maximal androgen blockade: facts and fallacies Endocr Relat Cancer 5 1998 353 356
55. A.V. Kaisary, C.J. Tyrrell, W.B. Peeling, and K. Griffiths Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma Br J Urol 67 5 1991 502 508
56. N.J. Vogelzang, G.W. Chodak, M.S. Soloway, N.L. Block, P.F. Schellhammer, and J.A. Smith Jr. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group Urology 46 2 1995 220 226
57. J. Seidenfeld, D.J. Samson, V. Hasselblad, N. Aronson, P.C. Albertsen, and C.L. Bennett Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 132 7 2004 566 577
58. H. Parmar, L. Edwards, R.H. Phillips, L. Allen, and S.L. Lightman Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer Br J Urol 59 3 1987 248 254
59. F.M. Chu, M. Jayson, M.K. Dineen, R. Perez, R. Harkaway, and R.C. Tyler A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer J Urol 168 3 2002 1199 1203
60. C.F. Heyns, M.P. Simonin, P. Grosgurin, R. Schall, and H.C. Porchet For the South African Triptorelin Study Group. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer BJU Int 92 3 2003 226 231
61. M.S. Khan, and A. O'Brien An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate Urol Int 60 1 1998 33 40
62. D. Fontana, M. Mari, A. Martinelli, C. Boccafoschi, C. Magno, and M. Turriziani 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial Urol Int 70 4 2003 316 320
63. M.F. Sarosdy, P.F. Schellhammer, M.S. Soloway, N.J. Vogelzang, E.D. Crawford, and J. Presti Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer BJU Int 83 7 1999 801 806
64. B. Tombal Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol 4 5 Suppl 2005 14 19
65. R. Perez-Marreno, F.M. Chu, D. Gleason, E. Loizides, B. Wachs, and R.C. Tyler A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer Clin Ther 24 11 2002 1902 1914
66. E. Kienle, and G. Lubben Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group Urol Int 56 Suppl 1 1996 23 30
67. D. Jocham Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results Urol Int 60 Suppl 2 1998 18 24
68. P. Fernandez del Moral, G.A. Dijkman, F.M. Debruyne, W.P. Witjes, and G.J. Kolvenbag Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group Urology 48 6 1996 894 900
69. C.J. Tyrrell, J.E. Altwein, F. Klippel, C. Jurincic-Winkler, E. Varenhorst, and G. Lunglmayr Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group Eur Urol 37 2 2000 205 211
70. M. Rizzo, T. Mazzei, E. Mini, R. Bartoletti, and P. Periti Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial J Int Med Res 18 Suppl 1 1990 114 125
71. E. Bruun, and C. Frimodt-Moller The effect of Buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The "Danish Buserelin Study Group" Scand J Urol Nephrol 30 4 1996 291 297
72. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79(2): 235-46.
73. F.H. Schroder, K.H. Kurth, S.D. Fossa, W. Hoekstra, P.P. Karthaus, and M. Debois Members of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study J Urol 172 3 2004 923 927
74. F. Labrie, A. Dupont, A. Belanger, L. Cusan, Y. Lacourciere, and G. Monfette New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen Clin Invest Med 5 4 1982 267 275
75. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989 17;321(7):419-24.
76. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group Lancet 346 8970 1995 265 269
77. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group Lancet 355 9214 2000 1491 1498
78. B. Schmitt, C. Bennett, J. Seidenfeld, D. Samson, and T. Wilt Maximum androgen blockade for advanced prostate cancer The Cochrane Database of Systematic Reviews 2005
79. D. Newling Advanced prostate cancer: immediate or deferred hormone therapy? Eur Urol 39 Suppl 1 2001 15 21
80. J.F. Caubet, T.D. Tosteson, E.W. Dong, E.M. Naylon, G.W. Whiting, and M.S. Ernstoff Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens Urology 49 1 1997 71 78
81. Saad F. Bisphosphonates in prostate cancer: where are we and where should we go? J Natl Cancer Inst 2003 3;95(17):1262-63.
82. N. Pandit-Taskar, M. Batraki, and C.R. Divgi Radiopharmaceutical therapy for palliation of bone pain from osseous metastases J Nucl Med 45 8 2004 1358 1365
83. F. Kraeber-Bodere, L. Campion, C. Rousseau, S. Bourdin, J.F. Chatal, and I. Resche Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement Eur J Nucl Med 27 10 2000 1487 1493
84. R. Sharifi, L.D. Knoll, J. Smith, and E. Kramolowsky Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer Urology 51 1998 271 276
85. The Leuprolide Study Group Leuprolide versus diethylstilboestrol for metastatic prostate cancer N Engl J Med 311 1984 1281 1286
86. J.E. Fowler, M. Flanagan, D.M. Gleason, I.W. Klimberg, J.E. Gottesman, R. Sharifi for the VIADUR study Group Evaluation of an implant that delivers Leuprolide for 1 year for the palliative treatment of prostate cancer Urology 55 2000 639 642
87. D.C. Bae, and B.S. Stein The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate J Urol 172 6 Pt 1 2004 2137 2144
88. J.L. Peters, A. Fairney, P. Kyd, A. Patel, S. Rogers, and J.J. Webster Bone loss associated with the use of LHRH agonists in prostate cancer Prostate Cancer Prostatic Dis 4 3 2001 161 166
89. T. Kotake, M. Usami, H. Akaza, K. Koiso, Y. Homma, and K. Kawabe Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group Jpn J Clin Oncol 29 11 1999 562 570
90. T. Tsushima, Y. Nasu, T. Saika, Y. Maki, M. Noda, and B. Suyama Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist Urol Int 66 3 2001 135 139